, Volume 5, Issue 2, pp 49-53

Vaccination against hepatitis a in patients with chronic liver disease

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Hepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with underlying chronic liver disease. HAV vaccination is effective and safe, although the vaccine is less immunogenic in patients with advanced liver disease. Despite recommendations to immunize patients with chronic liver disease, rates of HAV vaccination remain low, thus highlighting the need for public health programs to increase awareness about HAV vaccination.